Who Should Consider GLP-1 Therapy FDA indications for weight loss require: BMI 30 (obesity), or BMI 27 (overweight) with at least one weight-related condition hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, cardiovascular disease, or similar These thresholds set eligibility, but they don't answer the more important question: who benefits most
GLP-1 medications like semaglutide (Wegovy) and liraglutide (Saxenda) are MHRA-licensed prescription-only medicines that work by enhancing satiety and slowing gastric emptying rather than boosting metabolism
For those with diabetes, monitoring should include blood glucose checks as clinically indicated and hemoglobin A1c reassessment approximately 3 months after therapy changes, per American Diabetes Association guidelines
Risk of erectile dysfunction One of the more serious concerns is the risk of sexual dysfunction (ED)
Es trgt zur normalen Funktion von Nerven und Muskeln sowie zum Energiestoffwechsel bei